middle.news
Acrux Narrows FY26 Loss 90% as Female Testosterone Development Gains Momentum
9:27am on Wednesday 26th of August, 2026 AEST
•
Healthcare
Read Story
Acrux Narrows FY26 Loss 90% as Female Testosterone Development Gains Momentum
9:27am on Wednesday 26th of August, 2026 AEST
Key Points
46% revenue growth to $6.6 million
Net loss after tax narrowed 90% to $0.6 million
Focus shifts to Female Testosterone MDTS for HSDD
Phase II clinical success and FDA feedback received
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Acrux (ASX:ACR)
OPEN ARTICLE